Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 8:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 2,633 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intermediate dose Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Interaction Study Between TMC435, Atorvastatin and Simvastatin in Healthy Participants

NCT01689623
View directory record Official record
Conditions
Healthy Participants
Interventions
TMC435, Atorvastatin, Simvastatin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

NCT02556918
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Oct 24, 2026, 8:59 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

NCT05399888
View directory record Official record
Conditions
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
Interventions
Diranersen, Diranersen-matching placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 80 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
36
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants

NCT01000974
View directory record Official record
Conditions
Haemophilus Influenzae Type b
Interventions
GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108), ActHIB™, Pentacel™, Pediarix™, Prevnar 13™, Rotarix™, Engerix™-B, Infanrix™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
4,003 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
63
States / cities
Dothan, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 1 Interventional

Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM

NCT01357603
View directory record Official record
Conditions
Type1 Diabetes
Interventions
Glargine
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 60 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants

NCT00833482
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1 (HIV-1), HIV Infections
Interventions
Voriconazole, Atazanavir, Ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule

NCT02034773
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-220, Placebo
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor

NCT01899105
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
lumacaftor, ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 2 Interventional Results available

Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder

NCT02044094
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine, buprenorphine and naloxone, hydromorphone, placebo
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma

NCT01029054
View directory record Official record
Conditions
Multiple Myeloma
Interventions
carfilzomib, lenalidomide plus dexamethasone
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
4
States / cities
Ann Arbor, Michigan • St Louis, Missouri • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 24, 2026, 8:59 PM EDT
Completed No phase listed Observational

Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT

NCT03170817
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Cardiac Perfusion Rest/Stress Digital PET/CT, N-13 ammonia, Regadenoson
Diagnostic Test · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Respiratory Kinematics During Voluntary and Reflex Cough in Healthy Adults

NCT01854268
View directory record Official record
Conditions
Cough
Interventions
Healthy adults who receive capsaicin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Oct 24, 2026, 8:59 PM EDT
Recruiting Phase 2 Interventional

Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG

NCT07216391
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Antithymocyte Globulin (ATG), Teplizumab
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
4 Years to 34 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Aurora, Colorado • New Haven, Connecticut • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants

NCT04933682
View directory record Official record
Conditions
Healthy
Interventions
ALXN2050, Fluconazole, Rifampin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 24, 2026, 8:59 PM EDT
Recruiting Not applicable Interventional

Fuzzy Wale Compression Stockinet to Promote Healing Following Transtibial Amputation for Peripheral Arterial Disease

NCT06308562
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Fuzzy Wale Compression Stockinet
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 24, 2026, 8:59 PM EDT
Recruiting Phase 1 Interventional

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

NCT05794958
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Large B-cell Lymphoma
Interventions
Axicabtagene Ciloleucel
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2038
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating Distribution of a Tenofovir Douche With Tap Water Douching and Simulated Receptive Anal Intercourse

NCT04195776
View directory record Official record
Conditions
HIV/AIDS, HIV Prevention
Interventions
Tenofovir Douche
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 1Phase 2 Interventional

Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer

NCT01543659
View directory record Official record
Conditions
Prostate Cancer
Interventions
89Zr-DFO-huJ591
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 4 Interventional Results available

Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)

NCT00458835
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Ciclesonide
Drug
Lead sponsor
Covis Pharma S.à.r.l.
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

NCT02804750
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
CORT125134
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
12
States / cities
Laguna Hills, California • Aurora, Colorado • Fort Lauderdale, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN)

NCT04702997
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Bardoxolone methyl oral capsule, Placebo oral capsule
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 70 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
12
States / cities
La Mesa, California • Arvada, Colorado • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 24, 2026, 8:59 PM EDT
Terminated Phase 1 Interventional

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

NCT03275597
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IV
Interventions
Durvalumab, Tremelimumab, Stereotactic Body Radiotherapy
Drug · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 24, 2026, 8:59 PM EDT
Completed Early Phase 1 Interventional Results available

Proof of Principle Trial to Determine if Nutritional Supplement Conjugated Linoleic Acid (CLA) Can Modulate the Lipogenic Pathway in Breast Cancer Tissue

NCT00908791
View directory record Official record
Conditions
Breast Cancer
Interventions
Conjugated Linoleic Acid (CLA)
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Oct 24, 2026, 8:59 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

NCT06319820
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Neoplasms
Interventions
TAR-210, Gemcitabine, MMC
Combination Product · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
38
States / cities
Little Rock, Arkansas • Los Alamitos, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 24, 2026, 8:59 PM EDT